SKF makes remanufacturing work globally – Winner of SBCOP’s Best Cases

GOTHENBURG, Sweden, Nov. 10, 2025 /PRNewswire/ — At COP30 in Belém, Brazil, SKF will showcase scalable clean technologies and circular solutions to accelerate industrial decarbonization, reaffirming its commitment to innovation, circularity, and responsible growth. As a global leader in bearing and rotating equipment solutions, SKF continues to drive innovation that supports the transition to a net-zero future.

“The COP30 platform emphasizes that collaboration and partnerships are key to the climate transition, and we are proud to contribute with innovative and sustainable solutions that reduce environmental impact while delivering tangible value to industries worldwide,” says Annika Ölme, CTO and Senior Vice President, Technology Development.

Key technologies and initiatives on display will include energy transition, circular economy and materials. Remanufacturing and RecondOil are two examples of how SKF contributes to a circular future. Other solutions that SKF will present at COP30 are:

• Industrial heat pumps with ceramic and magnetic technologies.
• Energy-efficient HVAC systems powered by SKF magnetic bearings.
• Tidal power drivetrains for renewable energy generation.
• Internal decarbonization programs and a robust investment framework.

SKF wins SBCOP’s Best Cases

At COP30, SKF’s Remanufacturing solutions will be recognized as a winner of SBCOP’s (Sustainable Business COP) Best Cases. This award highlights SKF’s commitment to sustainability and its pioneering efforts in extending product lifecycles, reducing waste, and minimizing carbon emissions through advanced remanufacturing practices.

“At SKF, we demonstrate our credibility and progress on our own science-based net-zero journey, applying the same ambitious standards internally as we advocate for externally. By actively decarbonizing our operations, investing in circularity, and ensuring supply chain transparency, our leadership is built on verifiable action and technological innovation,” says Annika Ölme.

Accelerating industrial decarbonization

SKF’s remanufacturing initiative exemplifies how clean technologies and circular solutions can accelerate industrial decarbonization. Remanufactured bearings perform like new—at a lower cost, with shorter lead times, and a significantly reduced manufacturing CO₂ footprint. The process ensures the same product quality and standards, with no shortcuts.

SKF RecondOil double separation technology (DST) enhances the circularity of industrial oil by regenerating it into a reusable asset, preventing it from aging and eliminating the need for new oil purchases. This reduces waste, cuts emissions, and improves machine performance.

“SKF has consistently driven sustainability through energy-efficient solutions, circularity, and emissions reductions in close collaboration with our customers. COP30 marks a strategic moment for SKF to step forward, share our learnings, and collaborate on global climate solutions,” says Sofie Runius Cederberg, Head of Sustainability.

The agenda and activities where SKF participates at COP30 is available on SKF at COP30: The world can’t afford friction – it’s time to scale what works | SKF

Media:

To book interviews with Annika Ölme, CTO and Senior Vice President, Technology Development, Sofie Runius Cederberg, Head of Sustainability, or other SKF participants at COP30, please contact Karin Markhede on karin.markhede@skf.com

Previous press release on similar topics:
20 October 2025: “SKF at COP30: The world can’t afford friction – it’s time to scale what works” [link]

04 November 2025: “SKF launches The Patent Bay, a platform for sharing technologies that could reduce environmental impact” [link]

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/skf/r/skf-presents-scalable-clean-technologies-and-circular-solutions-at-cop30–wins-sbcop-s-best-cases,c4264503

The following files are available for download:

BOSTON, Nov. 10, 2025 /PRNewswire/ — Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo during November 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-Generation Sequencing (NGS) library preparation.

By integrating AI-driven design and high-throughput assays, Fapon actively leverages its AI-enabled enzyme engineering platform to improve product performance. Its showcased enzymes and reagents are engineered to enhance the accuracy, efficiency, and reliability of molecular testing. Featured products include:

• MeloScript Reverse Transcriptase offers superior target adaptability, exceptional inhibitor tolerance, high thermastability and high sensitivity.
• ProPrime Taq DNA Polymerase delivers ultra-fast amplification, exceptional resistance to inhibitors and superior sensitivity.
• PreciAmp Bst DNA Polymerase enables fast LAMP amplification with high speed, high sensitivity and strong inhibitor tolerance.
• NextGen Universal FS DNA Library Prep Kit facilitates uniform enzymatic fragmentation, enhanced genome coverage, broad sample compatibility, and fast, automation-friendly library construction.

During the meeting & expo, Dr. Nick Guan, Vice President of Molecular Diagnostics R&D at Fapon Biotech, will host a corporate workshop titled “Shaping the Future of Molecular Testing: Innovative Enzymes at the Core” on November 12, 2025. The session will explore how cutting-edge enzyme engineering drives next-generation PCR, NGS, and Isothermal Amplification technologies.

Fapon aims to provide industry-leading, high-quality molecular enzymes and reagents to empower customers with advanced molecular diagnostics. Additionally, Fapon has reinforced its commitment to the U.S. market with a dedicated Boston-based R&D center focused on enzyme innovation and a local warehouse for streamlined customer support.

To schedule a meeting at the event, please contact market@fapon.com.

About Fapon

Fapon, a globally leading life sciences organization, is redefining the R&D paradigm in diagnostics and therapeutics through a cutting-edge “AI-driven + a closed loop of dry and wet experiments” model. This approach significantly accelerates novel biomarker/target discovery and translation. We have established an integrated business structure that combines AI-powered innovative discovery, one-stop diagnostic solutions and novel therapies. Our products and services have covered the full spectrum of health management across the entire lifecycle, and accelerated the development of precision medicine.

Follow us on LinkedIn (Fapon) or visit our website at https://us.faponbiotech.com/ 

NANJING, China, Nov. 10, 2025 /PRNewswire/ — Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD). The first dose was achieved in Hangzhou First People’s Hospital.

This randomized, double-blind, placebo-controlled, multi-center Phase II study is aiming to evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278 in participants with moderate-to-severe AD.

Atopic dermatitis is a chronic, recurrent, inflammatory skin disease characterized by symptoms such as dry skin, intense itching, and erythema, which significantly impact patients’ quality of life.  As a high medical need for the treatment of moderate to severe AD remains, there are opportunities to further optimise treatment options and technologies.

The critical role of Treg cells in peripheral immune tolerance is a major focus in current immunology research and was recently awarded the 2025 Nobel Prize. SIM0278 was developed on Simcere’s proprietary protein engineering platform. Its mechanism of action involves introducing mutations that reduce its affinity for effector T cells while maintaining high affinity for Tregs. This selectivity allows SIM0278 to activate Tregs specifically, helping to restore immune balance without affecting effector T cells or natural killer cells and shows potential for treating a variety of immune disorders. SIM0278 has demonstrated good tolerability, appropriate pharmacokinetic properties, and preliminary efficacy in the completed Phase I clinical study in China. It is expected to achieve sustained efficacy and become a best-in-class (BIC) product.

“We are excited about what SIM0278’s entry into Phase II means for AD patients and the long-term management of the disease. This partnership reinforces our commitment to pushing the boundaries of science and patient-centric innovation to deliver impactful solutions for unmet dermatological needs”, said Karl Ziegelbauer, Chief Scientific Officer at Almirall.

“The clinical progress of SIM0278 significantly strengthens Simcere’s leading position in the field of autoimmune diseases.” Said Dr Aik H Goh, MD , Chief Medical Officer of Simcere,” The initiation of Phase II clinical trials also marks a significant step forward in the project’s global clinical development plan. We look forward to working with our partner to bring this innovative drug to patients worldwide as soon as possible.”

In September 2022, Simcere signed an exclusive license agreement with Almirall, S.A., granting Almirall rights to develop and commercialize SIM0278 for all indications outside Greater China. The Phase I clinical study conducted by Almirall in the United States has been completed and a Phase II study on another skin condition will start in the coming months.

About Simcere

Simcere Pharmaceutical Group Limited（2096.HK） is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore areas with significant unmet needs, and our mission is Providing Today’s Patients with Medicines of the Future. Our industry-leading capabilities and commitment to synergistic innovation have enabled various global strategic collaborations and we are seen as the partner of choice by industry peers, medical institutes, and research organizations across the globe.

BEIJING, Nov. 10, 2025 /PRNewswire/ — Origin Agritech Ltd. (NASDAQ: SEED) (the “Company” or “Origin”), a leading Chinese agricultural technology company, today announced it has entered into a patent license agreement with Shandong Shunfeng Biotechnology Co., Ltd. (“Shunfeng BioTech”) for the Cas-SF01 gene editing tool. This collaboration grants Origin long-term access to fully IP-protected gene editing technologies, providing a solid foundation for the Company’s future research and development in trait gene editing. It also aims to accelerate the adoption of advanced gene editing technologies in corn breeding, marking a significant milestone in Origin’s efforts to develop high-density, high-yield, and adaptable corn varieties.

Advancing Breeding with Gene Editing Technology

The partnership builds upon Origin Agritech’s long-term collaboration with China Agricultural University. Together, they identified two key regulatory genes controlling corn leaf angle—ZmRAVL1 and ZmDWF4—whose functional studies have been published in Science and Nature, respectively.

Using Shunfeng BioTech’s proprietary Cas-SF01 gene editing platform, researchers successfully developed a series of edited corn induction lines, including ZmRAVL1-KO1 and ZmDWF4-KO1.

Origin’s acquisition of these edited corn induction lines addresses three strategic objectives:

• Biosafety Compliance: Essential for completing evaluations required for agricultural gene editing
• Direct Breeding Resources: Immediate application in future commercial hybrid development
• Core Technology Foundation: Central to Origin’s “Smart Plant Architecture” corn breeding program

Technological Breakthrough: “Smart Plant Architecture” for Enhanced Yields

Functional validation demonstrates that ZmRAVL1-KO1 and ZmDWF4-KO1 effectively optimize corn leaf angle, creating a canopy structure characterized by compact upper leaves and open lower leaves. This “smart plant architecture” significantly improves field light interception and airflow, enabling higher planting density and greater yield potential.

“Enhancing corn yield through increased planting density has long been a global breeding goal, but traditional methods have limited progress,” said Mr. Bill Deng, VP and Head of R&D at Origin Agritech. “These edited induction lines enable precise and efficient improvement of plant architecture in elite germplasm. Combined with our proprietary Hi-3 induction line gene editing technology, we can complete variety upgrades rapidly while avoiding the genetic drag associated with conventional backcrossing.”

Commercialization Roadmap: Advancing Biosafety Evaluation

Origin Agritech has initiated the biosafety assessment process for the edited lines. Additionally, this license agreement provides a substantial advantage by facilitating biosafety approval for Origin’s current and future gene editing transformants utilizing Hi-3 one-step gene-editing method, for some of which the Company has already applied. The Company estimates obtaining final biosafety certification will require 1-2 years due to regulatory procedures and experimental timelines. Origin is committed to advancing this process and accelerating the commercialization of its gene editing innovations.

Mr. Deng continued, “The signing of this patent license agreement marks a significant step forward in Origin Agritech’s gene editing breeding strategy. By integrating world-class research resources with innovative biotechnological tools, we are building a modern breeding innovation system with proprietary intellectual property, contributing to China’s agricultural technology advancement and national food security.”

About Origin Agritech Limited

Origin Agritech Limited, founded in 1997 and headquartered at the Origin R&D Center in Songzhuang, Tongzhou, Beijing, is a leading agricultural technology company in China. In crop seed biotechnologies, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust biotechnology seed pipeline, including products with glyphosate tolerance and Bt (pest resistance) traits. For further information, please visit the Company’s website at www.originagritech.com. The Company also maintains an X account to update investors on company and industry developments, which can be found at https://x.com/origin_agritech.

Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the federal securities laws, including Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements address expected future business and financial performance and financial condition and contain words like “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “will,” “would,” “target,” and similar expressions and variations. Forward-looking statements address matters that are uncertain. Forward-looking statements are not guarantees of future performance and are based on assumptions and expectations that may not be realized. They are based on management’s current expectations, assumptions, estimates, and projections regarding the Company and the industry in which it operates, but involve a number of risks and uncertainties, many of which are beyond the Company’s control. Some of the important factors that could cause the Company’s actual results to differ materially from those discussed in forward-looking statements are: failure to develop and market new products and optimally manage product life cycles; ability to respond to market acceptance, rules, regulations and policies affecting our products; failure to appropriately manage process safety and product stewardship issues; changes in laws and regulations or political conditions; global economic and capital markets conditions, such as inflation, interest and currency exchange rates; business or supply disruptions; natural disasters and weather events and patterns; ability to protect and enforce the Company’s intellectual property rights; and separation of underperforming or non-strategic assets or businesses. The Company undertakes no duty or obligation to publicly revise or update any forward-looking statements as a result of future developments, new information, or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure that such expectations will be correct. Actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein. You are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

For more information, please contact:

Origin Agritech Limited Contact:
Kate Lang (Mandarin/English)
Director of Investor Relations
Phone: +86 186-1839-3368
Email: bing.lang@originseed.com.cn

Investor Relations Contact:
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com